Inside Spark Therapeutics' Investigational SPK-8011 for Hemophilia A

<p>Spark Therapeutics&apos; Clinical Development Lead, Hematology, Dr. Tiffany Chang explains the company&apos;s data from its ongoing Phase 1/2 clinical trial of investigational SPK-8011 for hemophilia A, the largest gene therapy trial in this disease to date as well as the misconceptions and unknowns about the disease.</p>